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Abstract
Objective To describe the prevalence of nausea and vomit-
ing during radiotherapy and to compare quality of life,
psychological and functional status in patients experiencing
or not experiencing nausea.
Materials and methods A cross-sectional selection of 368
cancer patients treated with radiotherapy answered a
questionnaire (=93% answering rate) regarding nausea,
vomiting, actual use of and interest in antiemetic treatment,
quality of life and psychological and functional status
during the preceding week of radiotherapy. Mean age was
60 years and 66% were women.
Main results Nausea was experienced by 39% (145) and
vomiting by 7% (28) of patients in general, by 63% in
abdominal or pelvic fields and by 48% in head/neck/brain
fields. Abdominal/pelvic field (Relative risk (RR) 2.0), age
≤40 years (RR 1.9) and previous nausea in other situations
(RR 1.8) implied an increased risk for nausea. Antiemetics
were used by 17% and 78%were interested in or wanted more
information about acupuncture treatment against nausea. Of
the 145 nauseous patients only 25% felt that antiemetics had
helped them and 34% would have liked additional treatment,
although the nausea intensity was mild in 72%. The nauseous
patients reported lower well-being and quality of life, lower
satisfaction with aspects of daily living and more frequent
anxiety and depressed mood than the patients without nausea.
Conclusions Of all patients undergoing radiotherapy, 39%
experienced nausea and one third of them would have liked
more treatment against the nausea. This study stresses the
importance to identify and adequately treat patients with
increased risk for nausea related to radiotherapy.
Keywords Antiemetics . Daily living . Risk factors .
Vomiting . Quality of life
Introduction
Nausea is one of the most widely feared symptoms and it is
ranked among the most incapacitating side effects experi-
enced during cancer treatment [6, 22, 50]. Many studies
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have focused on nausea induced by chemotherapy, but less
attention has been addressed to radiotherapy-induced
nausea [31, 52]. Little is documented about how satisfied
patients are with their antiemetic treatment and how
nauseated patients experience quality of life and the daily
life situation during radiotherapy.
The frequency of nausea during radiotherapy varies
depending on the site being irradiated. For example, total
body irradiation causes nausea more often (80–100% of
patients) [46] than radiation to specific fields (39% in
general) [25]. Also, single dose treatments more often
(80%) lead to nausea albeit with shorter duration than
fractionated treatments [16, 17]. Studies regarding radio-
therapy-induced nausea have focused on evaluating a
specific antiemetic drug, mostly in total body irradiation,
half body irradiation or upper abdomen irradiation rather
than observing the prevalence of nausea and vomiting in
radiotherapy patients in general, treated in a normal clinical
setting [31]. That limits the application of those study
results to a general population undergoing radiotherapy.
Some exceptions exist; for example, an Italian study by
IGARR [25], showing that 39% of 914 radiotherapy
patients in general experienced nausea or vomiting. The
prevalence varied between 19% in fields including the skin
or extremities to 71% in upper abdominal fields. The risk
for nausea and vomiting increased when the size of
radiotherapy field was over 400 cm2 [25]. Other risk factors
than radiotherapy treatment-related variables, have not been
widely explored as factors in radiotherapy-induced nausea.
IGARR [25] found that previous chemotherapy increased the
emetic risk. However, risk factors associated with chemo-
therapy-induced nausea may also be applicable for radio-
therapy-induced nausea [2, 17, 23]. Lower age, female
gender, low alcohol intake, anxiety and previous experience
of nausea in other situations such as previous chemotherapy
indicate an increased risk for chemotherapy-induced nausea
[9, 13, 44] and are factors that would be interesting to
evaluate further as factors in radiotherapy-induced nausea.
For radiotherapy-induced nausea and vomiting there are
international antiemetic guidelines [17, 27, 31] but how
they are transferred into daily clinical practice and how
satisfied the patients are with their antiemetic treatment is
not well investigated. Some clinics offer non-pharmacolog-
ical methods such as acupuncture as a complement to
antiemetics [14] but the interest in undergoing acupuncture
treatment in patients with radiotherapy-induced nausea has
not, to our knowledge, been studied.
Studies have shown that chemotherapy-induced nausea
and vomiting reduce well-being [11], quality of life [3, 30,
32], performance of daily activities [30, 33, 34], ability to
socially interact [30] and increases anxiety and low mood
[43]. However, [30] radiotherapy-induced nausea is general-
ly less frequent and less severe than chemotherapy-induced
nausea [42] and it is not known to what extent these findings
are also valid for patients with nausea during radiotherapy.
The objective of this study was to describe the
prevalence of nausea and vomiting, the use of and
satisfaction with treatment against nausea, and to identify
risk factors for nausea during radiotherapy. Another
objective was to compare quality of life and psychological
and functional status as reported by patients experiencing
nausea and by those not experiencing nausea.
Materials and methods
A descriptive epidemiological design [49] was used. The
study has been approved by the Regional Ethics Committees.
Participants
A cross-sectional selection was made on four different days
at the radiotherapy departments of two Swedish University
hospitals, 2 days at each hospital. Both hospitals cover a
region in which patients live in cities as well as rural areas.
Potential participants were identified by research nurses at
each department and received written information about the
study. The study cohort consisted of all individuals 18 years
or older, irrespective of cancer diagnosis, who received
curative or palliative radiotherapy, giving informed consent,
could communicate in Swedish and understood the proce-
dure of the study. The exclusion criteria were any kind of
illness of such severity that the patient could not manage
participating in the study. The study intended to describe
the ordinary clinical situation. Antiemetics were prescribed
according to the normal clinical routines by the patients’
oncologist.
Study variables
Clinical data (cancer diagnosis, irradiated field and dose)
were extracted from the patients’ medical record and data
from a study-specific questionnaire were collected. The
questionnaire was in 20 radiotherapy patients, not included
in this study, tested for face-validity as follows: the
questionnaire was developed through interviews, was filled
in by the 20 patients and was then changed until the
investigator was certain that all the questions were correctly
understood and could be answered appropriately.
Questions regarding demographic data, for example age,
level of education, marital and work status were included
(Table 2). Questions regarding experience of previous
nausea when travelling by car, boat or plane, nausea related
to unpleasant smells or sights, in worrying situations,
during pregnancy and during eventual previous chemother-
apy and radiotherapy were also included.
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The questionnaire also included questions about the
week preceding the day on which the questionnaire was
given. The prevalence and intensity of nausea were
evaluated using the question: “Have you experienced
nausea during the past week?”, which was answered on a
four-level category scale: “No, not at all”, “Yes, a little,
“Yes, moderately”, “Yes, much”. The patient’s subjective
opinion regarding the reason for experiencing nausea was
expressed using structured answering categories with a
place for additional open answers. The number of vomiting
episodes was graded on a three-level category scale: “No
vomiting at all”, “Fewer than five vomiting episodes”,
“Five or more vomiting episodes”. The use of pharmaco-
logical or non-pharmacological antiemetic treatment was
registered. The satisfaction with the antiemetic treatment
was measured with two questions. The first was: “If you
received antiemetic treatment during the past week, have
you been helped by the treatment?” with the answering
categories: “Not relevant, I have not experienced nausea”,
“Yes, I have been much helped”, “Yes, I have been
moderately helped”, “Yes, I have been helped a little”,
“No, I have not been helped at all” and “No, I did not
receive any antiemetics at all”. The second question was
“Would you like to receive additional antiemetic treat-
ment?” with the answering categories “No, nausea is not a
problem”, “No, I have chosen not to take antiemetics”,
“Yes, I would like to receive additional treatment” and
“Yes, I have not received any antiemetic treatment at all”. A
question about willingness to try acupuncture was phrased:
“If it in the future was possible to choose acupuncture for
the treatment of nausea, would you like to try acupunc-
ture?”. The answering categories were: “Yes, without any
pharmacological antiemetics”, “Yes, as a complement to
antiemetics” “I am not sure, I would like to receive more
information” and “No, probably not”.
Other questions covered “physical and psychological
condition” (five items), “quality of life” (one item) and
“satisfaction with the daily living situation” (seven items)
during the past week. For details, see Table 1.
Procedure
The patients received the questionnaire at their ordinary
radiotherapy treatment session, answered it in private and
sent it to the study coordinator, using a prepaid envelope.
One reminder by phone was made if the patients had not
sent in the questionnaire within 2 weeks after first receiving
it. In order to avoid bias when answering the questionnaire
the involved radiotherapy health care professionals did not
see the completed questionnaires.
Statistical methods
Descriptive statistics: number (n), proportion (%), mean
(m), standard deviation (sd), median (md), 25th and 75th
percentile and range, were calculated separately for patients
experiencing nausea (the four-level nausea question cate-
gorized: “Yes, a little, “Yes, moderately” and “Yes, much”)
and without nausea (“No, not at all”). We selected possible
risk factors for nausea (i.e. experiencing nausea previously
in other situations, clinical and demographic data; see
Table 2) and calculated nausea prevalence (n, %), relative
risk (RR) and 95% confidence intervals for the different
subgroups compared to a reference group. The reference
Table 1 Example of variables included in the data collection
Question Range Lowest category Highest category
Physical and psychological condition the preceding week 8-graded scale 0 to 7
How would you describe your psychological well-being? Very poor Excellent
What do you estimate your physical capacity to have been? Very poor Excellent
How would you describe your total capacity? Very poor Very energetic
Have you felt anxiety? Never All the time
Have you felt depressed or in a depressed mood? Never All the time
Quality of life 8-graded scale 0 to 7 Very poor Excellent
How would you describe your totally quality of life
during the past week?
Daily living 8-graded scale 0 to 7 Not satisfied at all Completely satisfied
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group (RR 1.0) was defined as the subgroup with the lowest
prevalence of nausea. One exception from this procedure
was made when analyzing irradiated sites. The breast
region was chosen as reference group since the category
with the lowest prevalence of nausea (“Other” region)
consisted of only seven patients. Variables that could have
been affected by nausea, for example anxiety, depressed
mood, quality of life and satisfaction with the daily living
situation, were compared between patients with and without
nausea using Mann–Whitney U test. The statistical analyses
Table 2 Patient characteristics and relative risks for nausea
Variables Totally Experiencing nausea Free from nausea RR (95% CI)
All patients 368 145 (39) 223 (61)
Irradiated sites
Breast 160 50 (31) 110 (69) 1.0 (Ref.)
Abdomen or pelvis 62 39 (63) 23 (37) 2.0 (1.5–2.7)a
Mediastinum 25 9 (36) 16 (64) 1.2 (0.7–2.0)
Head and Neck 37 17 (46) 20 (54) 1.5 (1.0–2.2)
Prostate or bladder 55 18 (33) 37 (67) 1.0 (0.7–1.6)
Brain 22 10 (45) 12 (55) 1.5 (0.9–2.4)
Other, ex. extremities 7 2 (29) 5 (71) 0.9 (0.3–3.0)
Accumulated dose (Gray): m, SD 24.8±14.4 23.8±13.8 25.4±14.7
Gender
Male 125 (34) 47 (38) 78 (62) 0.9 (0.7–1.2)
Female 243 (66) 98 (40) 145 (60) 1.0 (Ref.)
Age years: m, SD 60.0±12.2 57.9±13.7 61.4±10.8
Range 19–86 19–86 19–86
19–40 23 (6) 14 (61) 9 (39) 1.9 (1.3–2.7)a
41–60 165 (45) 72 (44) 93 (56) 1.3 (1.0–1.7)
61–86 180 (49) 59 (33) 121 (67) 1.0 (Ref.)
Country of birth
Sweden 320 (87) 120 (38) 200 (62) 1.0 (Ref.)
Other country 48 (13) 25 (52) 23 (48) 1.4 (1.0–1.9)
Marital status 367b 144b
Married/living together 261 (71) 96 (37) 165 (63) 1.0 (Ref.)
Not married/living alone 106 (29) 48 (45) 58 (55) 1.2 (0.9–1.6)
Education 367b 222b
University 120 (33) 56 (47) 64 (53) 1.3 (1.0–1.7)
Primary/secondary school 247 (67) 89 (36) 158 (64) 1.0 (Ref.)
Religion 365b 143b
Christian/other religion 306 (84) 113 (37) 193 (63) 1.0 (Ref.)
Non-believer 59 (16) 30 (51) 29 (49) 1.4 (1.0–1.8)
Other illness
Yes 248 (57) 105 (42) 142 (67) 1.3 (0.9–1.7)
No 120 (33) 40 (33) 80 (67) 1.0 (Ref.)
Nausea in previous chemotherapy
Not relevant, no previous chemotherapy 293 (80) 114 (39) 179 (61) 1. 0 (Ref.)
Yes 20 (5) 9 (45) 11 (55) 1.2 (0.7–1.9)
No 55 (15) 22 (40) 33 (60) 1.0 (0.7–1.5)
Nausea during pregnancy 365b 143b
No 241 (66) 90 (37) 151 (63) 1.0 (Ref.)
Yes 124 (34) 53 (43) 71 (57) 1.1 (0.8–1.5)
Previous nausea in any situation 366b 144b 222b
No 114 (31) 29 (25) 85 (75) 1.0 (Ref.)
Yes 252 (69) 115 (46) 137 (54) 1.8 (1.3–2.5)a
N of previous nausea indicators, Md, 25th–75th percentile 1, 0–2 1, 1–4 1, 0–2
0–4 indicators 325 (88) 119 (37) 206 (63) Ref.
5–9 indicators 43 (12) 26 (60) 17 (40) 1.7 (1.2–2.2)a
RR Relative risk, CI 95% confidence interval, M mean, SD one standard deviation, Ref. reference group with the lowest prevalence of nausea
a Statistical significant increased risk for nausea compared to the reference group
b Number who answered the question
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were based on all the answer categories (null to seven) for
each question seen in Table 1, but the answer categories
were categorized (null to two, three to five and six to seven)
when presented in Fig. 1. The level of statistical signifi-
cance was set at a confidence interval not including 1, or
p<0.03, to adjust for multiple testing to avoid type-1 errors.
Results
During the four days of data collection, 476 patients were
scheduled to have radiotherapy. Of those, 58 were too ill to
participate and 22 did not give their informed consent, leaving
396 who were included in the study. Twenty-eight patients did
not answer the questionnaire after one reminder while 368
answered the questionnaire (93%), 125 men and 243 women.
For characteristics of the patients, see Table 2. A typical
patient included in the study was a 60-year-old woman who
received radiotherapy to the breast region for an accumulated
dose of 24.8 Gray, not combined with chemotherapy.
Risk factors for nausea
Among the 368 patients, 145 (39%) experienced nausea
during the past week of radiotherapy. The factors associated
with an increased risk for experiencing nausea were
radiation over pelvic or abdominal fields (63%), age
younger than 40 years (61%) and previous experience of
nausea in other situations (Table 2).
Nausea and vomiting
The nausea intensity was graded as “little” in 104 (72%) of
those 145 patients who experienced nausea the past week.
There was a greater percentage of patients treated over
abdominal or pelvic fields who experienced at least
moderate nausea (n=15 of 62, 24%) (Table 3) than among
the nauseated patients treated over other fields (n=26 of
306, 8%), RR 2.8, 95% C.I. 1.6–5.1.
Ninety-five of the 145 nauseated patients expressed their
own opinions concerning the reasons for experiencing
nausea: 77 (81%) thought that radiotherapy was the only
reason while eighteen (19%) patients mentioned other
factors that could have produced nausea—pharmacological
treatment (eight), the tumor itself (three), chemotherapy
(three), another disease (three) and travelling (one).
Of the 368 radiotherapy patients, 28 (7%) had vomited
during the preceding week, with higher prevalence in
patients treated over the abdominal or pelvic fields (n=9,































































































































































































































































Fig. 1 Self-assessed physical and psychological outcomes, global
quality of life and satisfaction in daily living situations in patients with
and without nausea (n=368). Assessments on an 8-grade scale, 0=
lowest possible and 7=highest possible. Percentages of patients
without nausea (n=223) and with nausea (n=145) last week. a
P<0.001 b P=0.001 c n=367, dn=366, en=305, fn=358
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Treatment against nausea
Of all the 368 patients, 61 (17%) had taken some kind of
antiemetics and 16 (4%) had received 5-HT3 receptor
antagonists during the past week of radiotherapy.
Of the 145 patients who experienced nausea during the
preceding week, 45 (31%) had taken at least one antiemetic
drug, 11 (8%), had taken two drugs and one patient had
taken three drugs. A fourth (n=36) of the nauseous patients
stated that they had received antiemetics that had helped
them at least to a moderate extent. Fifty (34%) of the 145
nauseous patients would have liked additional treatment
against their nausea while 58 (40%) had decided not to take
antiemetics (Table 4).
The use of antiemetics was more frequent in the 62
patents who were treated over the abdominal or pelvic
fields compared to the patients treated over other fields; 28
(45%) of the 62 patients had been taking some kind of
antiemetics during the preceding week and 6 (10%) had
received a 5-HT3 receptor antagonists.
None of the 368 patients reported use of any non-
pharmacological treatment against nausea. Forty percent
(145/361 who answered the question) said that they would
like to try acupuncture to treat nausea, if acupuncture was
made available—67 (19%) without any pharmacological
antiemetics and 78 (22%) as a complement to antiemetics.
One hundred thirty-six (38%) were not sure and asked for
more information about the method while 80 (22%)
answered that they probably not would try acupuncture.
Quality of life, physical and psychological conditions
and satisfaction with aspects of daily living
The 145 patients who experienced nausea rated their quality
of life, physical capacity, well-being and energy level lower
and had more frequent anxiety and depressed mood
compared to the 223 patients who had been free from
nausea during the week (Fig. 1). A smaller proportion
(13%) of the patients who experienced nausea ranked their
quality of life as very high or high (6–7 on the scale)
compared to 43% of the patients without nausea. Approx-
imately a fourth of the patients who experienced nausea
rated their well-being as very good or good (6–7 on the
scale) compared to half of the patients who were free from
nausea. Approximately half of the nauseous patients (51%)
and a third (30%) of the patients free from nausea graded
three or more (out of maximum seven) on the question
covering depressed mood. The patients who reported
nausea also graded lower satisfaction with all aspects of






Type of antiemeticsa 71
Anti-histamines 28
Dopamine receptor antagonists 26
Serotonin (5TH3)-receptor antagonists 12
Corticosteroids 3
Neuroleptics with antiemetic effects 2
Combinations of antiemetic types
Anti-histamines and serotonin (5TH3)-receptor
antagonists
2
Dopamine receptor antagonists and serotonin
(5TH3)-receptor antagonists
5
Corticosteroids and serotonin (5TH3)-receptor
antagonists
1
Anti-histamines and dopamine receptor antagonists 2
Dopamine receptor antagonists and
neuroleptics
1
Anti-histamines, dopamine receptor antagonists
and serotonin (5TH3)-receptor antagonists
1
Had help from medications 144b
Experiencing nausea, did not receive antiemetics 96 (67)
To a large extent 27 (19)
To a moderate extent 9 (6)
To a little extent 10 (7)
Not at all 1 (1)
Do not know 1 (1)
Ask for additional antiemetic treatment 141b
No, nausea is not a problem 33 (23)
No, have chose to not take antiemetics 58 (41)
Yes, ask for additional treatment 33 (23)
Yes, ask for treatment, have not received
any treatment
17 (12)
a The number of antiemetics taken was 71, because 12 patients
received more than one drug (range 1–3)
b Number who answered the question
Table 3 Prevalence of nausea and vomiting during the past week
Totally, n (%) Abdominal or pelvic
fields, n (%)
Number of patients 368 62
Nausea
Md Little Little
25th–75th percentile Little–little Little–moderate
No 223 (61) 23 (37)
Yes, little 104 (28) 24 (39)
Yes, moderate 27 (7) 11 (18)
Yes, much 14 (4) 4 (6)
Vomiting
No 340 (92) 53 (85)
Yes, <5 episodes 20 (5) 6 (10)
Yes, ≥5 episodes 8 (2) 3 (5)
Md median
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the daily living situation, seen in Fig. 1, compared to the
patients without nausea.
Discussion
This study showed that of all patients undergoing radio-
therapy, during a typical week of treatment 39% experi-
enced nausea and 7% vomited. Radiotherapy targeted to the
pelvic or abdominal field indicated an increased risk of
nausea (63%) and so too did an age younger than 40 years
and prior experience of nausea. Of those patients who
experienced nausea, only a fourth felt that antiemetics had
helped them at least moderately while a third would have
liked additional antiemetic treatment. The patients who
experienced nausea reported lower satisfaction with aspects
of daily living, lower well-being and quality of life, lower
total energy and physical condition and experienced more
frequent anxiety and depressed mood than the patients
without nausea.
The findings that during a typical week of radiotherapy,
39% patients in general, 63% of the patients treated over
abdominal or pelvic fields and 46% of patients treated over
head, neck or brain fields experienced nausea were quite
similar he findings reported by IGARR [25]. IGARR found
that 39% of patients in general, 71% treated over
abdominal fields and approximately 40% treated over the
brain, head and neck region experienced nausea or
vomiting during their radiotherapy period. Other previous
findings on the prevalence of radiotherapy-induced nausea
are based on studies evaluating the effect of antiemetics.
Mystakidou et al. [36] included 288 radiotherapy patients
and found that nausea was experienced by 58% of 50
patients irradiated over the abdominal field, 61% of 56
patients irradiated over the thoracic field, 64% of
47 patients irradiated over the cerebral region. It is in-
teresting to note that irrespective of the radiated field, the
prevalence was rather high. Maranzano et al. [31] divided
the emetic risk into four levels; high risk (>90%) in total
body irradiation, moderate risk (60–90%) in upper abdo-
men, low risk (30–59%) in lower thoracic and pelvic region
and minimal risk (<30%) in cranium, breast, extremities
and head and neck field. Our study, as well as those from
IGARR [25] and Mystakidou et al. [36] may suggest that
the thoracic and pelvic fields should be classified as
producing moderate risk instead of low risk and head, neck
or brain field should be classified as low risk instead of
minimal risk for nausea.
It has previously been shown that lower age is associated
with an increased risk for chemotherapy-induced nausea [9,
13] and in our study, an age lower than 40 years indicated
an increased risk also for radiotherapy-induced nausea.
Earlier experience of nausea in any other situations, for
example during previous chemotherapy, indicated an
increased risk for nausea, which is in concordance with
previous literature [16, 17, 25].
One third of the nauseous patients would have liked
additional antiemetic treatment, indicating that in daily
radiotherapy practise, health care professionals may under-
estimate nausea, in line with several earlier studies [18, 23,
25]. Only one fourth of the patients who experienced
nausea during radiotherapy felt that antiemetics had helped
them at least moderately, which is a lower level of
satisfaction than with antiemetic treatment during chemo-
therapy. Bosnjak et al. [8] found that a large majority (88%)
of 136 chemotherapy patients stated that they were satisfied
with their antiemetic treatment. The control of symptoms
and satisfaction with the antiemetic treatment can be
considered to be important goals of care, since Bosnjak et
al. showed that patients who were dissatisfied with their
antiemetic treatment experienced lower quality of life.
Uncontrolled nausea and vomiting are risk factors for
development of anticipatory nausea, which typically occurs
after a previous negative experience of nausea and can
continue for several years [23]. The finding that many
patients considered their antiemetic treatment insufficient
may, besides under-treatment, be related to use of less
effective antiemetics. The proportion of all our study
patients who received antiemetics (17%) was about the
same proportion and 14% as reported by others (15%) [15,
25] but the proportion was in our study rather low also in
patients irradiated over abdominal/pelvic fields, especially
regarding use of 5-HT3 antagonists. The oncologists
treating patients in our study may have positive clinical
experiences from other types of antiemetics than 5HT3-
receptor antagonists. 5HT3-receptor antagonists are much
more expensive than other types of antiemetics. In some
cases, a wish to reduce prescription cost [1] may result in
the choice of a cheaper alternative. The low utilisation of
5-HT3 antagonists is not in line with evidence-based
suggestions for this patient group, both in older [19, 21,
35] and in more recently updated antiemetic guidelines
based on randomised controlled studies [17, 27, 31]. During
upper abdominal irradiation, it has been shown that a 5-HT3
antagonist given prophylactic (43% had nausea) was more
effective than placebo (58% had nausea) [28] and was more
effective than corticosteroids only [40]. A combined
treatment with a 5-HT3 antagonist and corticosteroids given
as prophylaxis had additional effects compared to a 5-HT3
antagonist combined with placebo (77% versus 88%
experienced nausea or vomiting) [37]. 5HT3-receptor
antagonists given prophylactic (50% had nausea) was more
effective than 5HT3-receptor antagonists rescue (65% had
nausea) [36]. There are differences between the antiemetic
guidelines regarding when and how 5-HT3 antagonists
should be prescribed. Abdominal and pelvic fields are
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classified as moderate risk for nausea by ASCO (American
Association of Clinical Oncology) [27] but pelvic fields as
low risk by MASCC (Multinational Association of Sup-
portive Care in Cancer) [31]. MASCC for low risk suggests
prophylaxis or rescue with 5-HT3 antagonists and for
moderate risk prophylaxis with 5-HT3 antagonists, possibly
combined with corticosteroids. ASCO for low as well as
for moderate risk suggests prophylaxis with a 5-HT3 antag-
onist or in some patients a dopamine receptor antagonist,
without corticosteroids [27]. It seems like the oncologists
have followed MASCC’s emesis risk-classification (pelvis=
low risk) but none of the antiemetic guidelines [27, 31].
Eighty-eight of the nauseous patients (61%) did not take
any antiemetics at all, which is not in concordance to any of
the guidelines. We can only hypothetically discuss the
plausible reasons for this under-treatment. As already
mentioned, it may be caused by an underestimation of the
problem; the patients in daily clinical practice may not
complain about the nausea for reasons such as “wanting to
be nice to the therapist” while the health care professionals
do not ask if the patient is bothered by nausea. Health care
professionals may estimate the nausea-risk as low or
minimal, or they may think that the patients will be
nauseous if they are asked about nausea occurrence.
Additional reasons for the low utilisation of antiemetics in
our study may be that the nausea was perceived as mild in
most patients (72%) and that 40% of the nauseous patients
stated they had decided not to take antiemetics. We have no
data on the reasons for choosing not to take antiemetics.
Those 40% may have been proposed or even prescribed
antiemetics, but have chosen not to take it; or they may not
have been properly informed about their risk for nausea and
thus not offered antiemetics. Hypothetically, one reason
may be that the patients were afraid of side effects related to
antiemetic consumption. In a study of 453 American
patients with cancer, the most common reasons for using
complementary medicine, in which acupuncture was in-
cluded, was a desire to feel hopeful (73%), a wish to use
non-toxic treatments (49%), and to control decisions
regarding their medical care (44%) [41]. The interest shown
for acupuncture treatment against nausea, seen in our study,
emphasizes the relevance to determine if acupuncture is
effective in patients who, as a complement to antiemetics,
want to try non-pharmacological treatments against nausea
during radiotherapy.
Although nausea was mild in 72% of the nauseated
patients, the nauseated patients reported lower satisfaction
with aspects of daily living, lower well-being and quality of
life, lower total energy and physical condition and more
frequent anxiety and depressed mood than the patients
without nausea. Nausea has, in studies concerning chemo-
therapy-induced nausea, seemed to cause substantial phys-
ical, psychological and functional distress for the patient [3,
18, 32–34, 39, 43]. Previous findings regarding the impact
of radiotherapy-induced nausea on quality of life are based
on studies evaluating antiemetics. Sykes et al. [51] found
that emesis-related quality of life was higher in a group of
33 palliative radiated patients treated with 5TH3-receptor
antagonists (30% experienced nausea) compared to a
control group including 33 patients treated with cortico-
steroids (72% experienced nausea). Global quality of life
did in our study differ between patients with and without
nausea but did not differ between the groups in the study by
Sykes et al., nor between a group including 75 patients
irradiated over upper abdomen treated with corticosteroids
(30% vomited or retched) compared to 76 patients
receiving placebo pills (51% vomited or retched) [26].
Radiotherapy induced nausea is commonly considered to be
less problematic than post chemotherapy nausea [42], but
our results indicate that also nausea during radiotherapy
may affect the patients’ daily life in several negative ways.
The usually long duration of nausea [16] may be one
conceivable explanation why patients with nausea, even if
mild in intensity, felt poorer in so many ways compared to
the patients free from nausea. Longer duration of nausea
decreased well-being in patients receiving chemotherapy,
even when nausea intensity was controlled for [11].
A strength in this study is the response rate to the
questionnaire (93%) which could be considered as very
high compared to five Swedish nationwide postal ques-
tionnaires comprising a total of 4,009 invited cancer
patients, individuals who have lost a family member in
cancer and healthy population controls. The total mean
response rate was 76% and varied for the patient groups
from 77% to 88% [38]. Reasons for the high response rate
in our study may be that the patients found the study
valuable and the questionnaire relevant. In addition, one
reminder by phone was made which is known to increase
answering rate. Another strength is the inclusion of a wide
variety of radiotherapy patients, not restricted to patients
receiving treatment over a specific field or receiving a
specific antiemetic agent. This indicates that our findings
are valid to a general radiotherapy population treated with
similar routines as in this study, but the radiotherapy
treatment routines may differ in an international perspec-
tive. The similarities with previous findings regarding
nausea incidence [25] support the validity of our findings.
However, the lack of longitudinal information makes it
impossible to describe the longitudinal history of nausea
and antiemetics taken. We avoided bias [49] by informing
patients that the health care professionals were not aware of
the patients’ answers. The construction and use of a study-
specific questionnaire has been described previously [4,
48]. The face-validation process made sure that the
questions and the grading of answers were appropriate for
this specific patient group. Nausea was measured with a
30 Support Care Cancer (2009) 17:23–32
category scale that is an established method to measure
nausea and has been demonstrated to have good correlation
with a visual analog scale [7, 10]. Several established
instruments are available to measure quality of life, but they
often include a large number of questions [47]. In this
study, single-item questions were instead chosen to measure
for example quality of life, anxiety, low mood and well-
being in order to minimize the patient burden, as suggested
by Sloan et al. [45] and Davaey et al. [12]. This kind of
simple measurement has produced results similar to those
from longer well-established questionnaires in measuring
quality of life [5, 20, 24], anxiety [12] and mood status
[38]. For measuring satisfaction with the daily living
situation, the available established instruments were not
suitable for our patient group. Lindeboom et al. [29] found
113 scales for measuring activities of daily living. Most of
the scales are not intended for self assessment or are limited
to specific patient groups (for example neurological
disabilities) or measure basic mobility and self-care, which
were not relevant for our patient group. Some methodology
issues regarding causality in the study need to be discussed.
For example, anxiety is known as a risk factor for
chemotherapy-induced nausea [9, 13, 44] and is also
suggested to be a risk factor for radiotherapy-induced
nausea. In our study, we do not have any longitudinal
information regarding the anxiety, so the variable anxiety
was excluded from the risk-analysis. We thus do not know
if anxiety is a predictor of or a consequence for nausea.
This study implies that patients with increased risk for
nausea should be identified and treated in advance, for
example those with a history of nausea. If patients, despite
preventive strategies, ask for additional antiemetic treat-
ment or chose to not take antiemetics, it is reasonable to
study if non-pharmacological treatments have effects on
radiotherapy-induced nausea and vomiting.
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